<DOC>
	<DOCNO>NCT00048126</DOCNO>
	<brief_summary>This study ass efficacy safety continuous oral Xeloda administration combination intravenous irinotecan first-line treatment patient advance and/or metastatic colorectal cancer . The anticipated time study treatment 3-12 month target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Xeloda ( Capecitabine ) Patients With Advanced and/or Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>adult patient &gt; =18 year age ; locally advance and/or metastatic colorectal cancer ; &gt; =1 target lesion . previous treatment Xeloda irinotecan ; previous systemic therapy metastatic disease ; progressive disease previous adjuvant therapy within 6 month completion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>